Bazedoxifene/conjugated estrogens, sold under the brand name Duavee among others, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis.[3][4][5] It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens.[3] It is taken by mouth.[3]
The combination was approved for medical use in the United States in October 2013,[6] and in the European Union in December 2014.[7]
See also
- List of combined sex-hormonal preparations
References
- Bazedoxifene / conjugated estrogens (Duavee) Use During Pregnancy Drugs.com, 16 February 2019, retrieved 23 June 2020^
- Duavive Product information Health Canada, 9 June 2023, retrieved 17 February 2025^
- Duavee- conjugated estrogens/bazedoxifene tablet, film coated DailyMed, 16 July 2021, retrieved 21 February 2022^
- Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women Drugs of Today, February 2015^
- The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause International Journal of Endocrinology, 2017^
- Drug Approval Package: Duavee (conjugated estrogens and bazedoxifene) NDA #022247 U.S. Food and Drug Administration (FDA), 7 October 2013, retrieved 23 June 2020^
- Duavive EPAR European Medicines Agency (EMA), retrieved 10 June 2020^